Human Immunodeficiency Virus (HIV) accessory protein Negative factor (Nef) is detected in the 21 plasma of HIV+ individuals associated with exosomes. The role of Nef+ exosomes (exNef) in HIV 22 pathogenesis is unknown. We perform a retrospective longitudinal analysis to determine 23 correlative clinical associations of exNef plasma levels in ARV-treated HIV+ patients with or 24 without immune recovery. exNef concentration in a subset of AIDS Clinical Trial Group (ACTG) 25 384 participants with successful virological suppression and with either high (∆ >100 CD4 cell 26 recovery/High Immunological Responders (High-IR) or low (∆ ≤100 CD4 cell recovery/ Low 27 Immunologic Responders (Low-IR) immunologic recovery was measured and compared for 28 study weeks 48, 96, and 144. CD4 recovery showed a negative correlation with exNef at study 29 week 144 (r = -0.3573, *p=.0366). Plasma exNef concentration in high IRs negatively correlated 30 with naïve CD4 count and recovery (r = -0.3249, *p = 0. 0348 (High-IR); r =0.2981, *p= #0.0513 (Low-31 IR)). However, recovery of CD4 memory cells positively correlated with exNef (r =.4534, 32 *p=.0358) in Low-IRs but not in High-IRs. Regimen A (Didanosine, Stavudine, Efavirenz) lowered 33 exNef levels in IRs by 2-fold compared to other regimens. Nef+ exosomes persist in ART-treated 34 HIV+ individuals despite undetectable viral loads, negatively correlates with naive and memory 35 CD4 T cell restoration and may be associated with reduced immunological recovery. Taken 36
Introduction 83
Murine Leukemia Virus) [28] [29] [30] [31] [32] . Given the immunomodulatory functions of exosomes, we 84 sought to explore whether exNef may selectively impair CD4+ T-cells recovery during cART. 85 For this study, Nef concentration was determined in plasma-derived exosomes isolated 86 from a subset of the ACTG-384 cohort with and without immune recovery post-cART. We show 87 that Nef+ exosomes persist and can be detected in study participants with undetectable viral 88 loads even after 144 weeks of therapy. This suggests that exNef production is independent of 89 plasma viral load. Interestingly, we demonstrate that Low-IRs have significantly higher levels of 90 exNef compared to High-IRs at 144 weeks post-treatment. Recovery of naive CD4 T-cells 91 (CD45RA+, CD62L+) and total CD4 cells negatively correlated with exNef. Overall, we report that 92 Nef+ exosomes are detected in the plasma despite viral suppression and that exNef is negatively 93 associated with changes in naïve and total CD4 count. Taken together these results suggest that 94 exNef may ultimately affect CD4 T-cell recovery and be a biomarker of immune recovery. in ACTG 384 were used in this study [1] (Robbins, GK 2003; Shafer 2003 ). As previously 99 described ACTG 384 was a factorial multi-center randomized controlled trial conducted in the 100 United States and Italy that compared sequential three-drug regimens for treatment of HIV 101 infection. Nine hundred eighty ART-naive HIV-1+ subjects were randomized and treated with 102 stavudine/didanosine or zidovudine/lamivudine with nelfinavir, efavirenz, or both nelfinavir 103 and efavirenz. If virological failure occurred, then participants were placed on another regimen sequentially. In this study, samples from three distinct groups were obtained and assayed. The 105 groups included 1) Treatment failure (TF) defined as those with a virologic failure with a 106 detectable viral load ( HIV RNA > 50 RNA copies) what at any time point before 144 weeks, 2).
107
Immunologic responders defined as those with high CD4 improvement of > 100 cells/mm3 108 (achieved at any point post study initiation) and suppressed viremia (< 50 RNA copies) (High 109 IRs) and 3) Immunologic non-responders defined as those with CD4 improvement of < 100 110 cells/mm3 and suppressed viremia (Low IRs) ( Figure 1 ). To avoid confounding effects of 111 multiple-treatment regimens, the samples utilized for this sub-cohort were derived from subjects 112 on their first treatment regimen and those with samples from three-or four time intervals (0, 48, 113 96, and/or 144 weeks).
114
Isolation of plasma-derived exosomes. Plasma exosomes were isolated as previously described 115 [14, 23, 36] . Plasma was pre-cleared by centrifugation at 10,000g for 30 minutes to remove 116 particulates. Microvesicles were pelleted from pre-cleared plasma via ultra-centrifugation for 1 117 hour at 300,000 x g and then re-suspended in 250 µl of phosphate buffered saline (PBS). Immune 118 complexes within the re-suspended exosomes were removed using acid-dissociation prior to Nef 119 measurement similar to p24 antigen measurements from plasma. Exosomes/high speed pellets 120 (100 µl) were treated with 100 µl of 0.3N hydrochloric (HCl, Sigma) and allowed to incubate for 1 121 hour at 37 C. The acid mixture was neutralized with 100 µl of 0.3N sodium hydroxide (NaCl, 122 Sigma) prior to assaying for Nef.
123
Nef Enzyme-linked Immunosorbent Assay (ELISA). Nef concentration in acid-dissociated 124 microvesicle/exosome preparations was measured using a commercially available anti-Nef 125 sandwich ELISA kit (Immunodiagnostics, Bedford, MA) according to the manufacturer's 126 instructions. Briefly, the neutralized microvesicle preparations were diluted 1:1 with sample 127 diluent (Component C) and added to ELISA plates coated with anti-Nef (Component A).
128
Following 1-hour incubation at room temperature the plates were washed three times with wash 
Results

144
Baseline characteristics of ACTG384 sub-cohort. This sub-cohort consisted primarily of males 145 (88.4%) ( Table 1) . Plasma HIV RNA levels at baseline were not significantly different between the three groups (range). Baseline CD4 counts were significantly different between groups (137 147 cells/mm3 in TF, 60 cells/mm3 in High IRs, 38 cells/mm3 in Low IRs) (as previously described 148 that CD4 count at the initiation of therapy may not play a role in immune recovery [3] . 149 Activated CD4 and CD8 T-cells were not significantly different between the High-and Low-IRs suppression that had CD4 recovery above or below 300 cells/mm 3 at study week 144 (Fig 1A) . At 184 study week 144, 40% of the sub-cohort exhibited discordant VL and CD4 cell recovery along with 185 increased exNef level. In the absence of detectable viral replication, exNef could be detected in 186 the plasma and the levels correlated with total CD4 recovery (Fig 1B) . (Fig 2A) . A retrospective longtitudinal analysis shows that at the initiation of therapy,
201
Nef levels were not significantly different between the Low_IRs and High_IRs (Fig 2A, upper   202 panel). However, by study week 144, the Low-IRs had significantly higher levels of plasma exNef 203 than the High IRs (Fig 2A, lower panel) . The median baseline plasma Nef level in the sub-cohort 204 at 48 weeks was approximately 2.5 ng per 1 ml plasma and by 144 weeks Nef levels increased to 205 almost 5 ng per 1 ml plasma in the Low IRs. In fact Low-IRs exhibit an increasing trend in exNef 206 levels from study weeks 48 through 144 while in High-IRs exNef level decreased over the study 207 ( Fig 2B) . This finding suggests that plasma exNef may play a role immunological recovery. 
216
Naïve CD4 count and recovery inversely correlate with exNef. We then investigated whether 217 Nef+ exosome levels correlated with recovery of naïve CD4 cell counts specifically.
218
Immunological recovery (as defined in Methods) 48 weeks post treatment and close to 90% (18 219 out of 20) by week 96 of treatment (Fig 3A) . However, none of the Low-IRs exhibited increases in 220
CD4 T-cell count close to 350 cells/mm 3 by 144 weeks (Fig 3A) . Although naïve T-cells do recover 221 in both High-or Low-IR the IRs have appreciably less naïve CD4 cells than the IRs 96-and 144 222 weeks post treatment initiation (Fig 3C) . Notably the changes in both CD4 T-cell count and CD4
223
naïve T-cells negatively correlated with the Nef concentration in plasma-derived microvesicles 224 (Fig 3, B and D) suggesting that in vivo microvesicular Nef may be associated with immune 225 recovery/ CD4 T-cell rebound. CD4 memory cell recovery. Interestingly at weeks 48 and 96 post-therapy High-IRs exhibited appreciably more CD4 memory cells than the Low_IRs (Fig 4, panel A) . The degree of CD4 236 increase directly correlated with exNef in the Low_IRs (Fig 4, panel B ), suggesting that CD4 237 memory cells could be one of the sources of exNef during anti-viral suppression. Table 2 . Basically, two NRTIs zidovudine and lamuvidine or didanosine and 248 stauvidine followed by either efavirenz or nelfinavir were compared (Fig 5A, upper panel) .
249
Previous results from the ACTG-384 cohort demonstrated that the combination of zidovudine, (Fig 5, lower panel) .
This suggests that drug regimen may also dictate exNef levels and that PI-sparing regimens 259 reduce both viral load and exNef level. indicator of CD4 immune recovery during HAART. 333 We posit that the increased level of Nef+ exosomes early in High_IRs (by week 48) are 334 indicative of reduced virus production and suggests that in the absence of productive viral 335 replication HIV-infected cells release more Nef+ exosomes. If these exosomes affect T-cell 336 activation or viability, then this may impact immune recovery. By 144 weeks however, exNef is 337 significantly reduced in High-IRs participants relative to Low-IRs participants. Taken together our study suggests that extended use of combination therapy lacking a HIV protease inhibitor 339 impairs the release of Nef+ exosomes while NRTI/NNRTIs have no long-term effects on exNef.
340
Overall, these data also suggest that increased Nef levels maybe a double-edged sword -in 341 terms of viral suppression-high exNef is associated with decreased viral load but in regard to suggesting that SMR peptides could be developed as a therapeutic agent.
347
Ultimately, we provide evidence of exNef as a novel virological factor contributing to the 348 dissociation of viral load and immunological recovery. Since, drug regimens can alter exNef 349 levels, therapies need to be developed that both successfully lower viral load and Nef+ exosomes 350 levels. Our findings also suggest that clinicians could monitor exNef level along with CD4 T-cell 351 count in patients undergoing ARV-treatment to assess the effectiveness of therapeutic regimens.
